Compare BLDP & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | CMPS |
|---|---|---|
| Founded | 1979 | 2020 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.9M | 724.5M |
| IPO Year | 2009 | 2020 |
| Metric | BLDP | CMPS |
|---|---|---|
| Price | $2.59 | $5.73 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $2.34 | ★ $26.57 |
| AVG Volume (30 Days) | ★ 3.5M | 2.0M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.21 | N/A |
| Revenue Next Year | $18.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $2.25 |
| 52 Week High | $4.10 | $8.90 |
| Indicator | BLDP | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 59.23 | 45.37 |
| Support Level | $2.55 | $4.90 |
| Resistance Level | $2.82 | $7.02 |
| Average True Range (ATR) | 0.13 | 0.32 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 93.06 | 85.51 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from United States followed by Poland, Canada, and other countries.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.